Rita Gandhy is a movement disorders neurologist and comes with over 4 years of experience at Roche/Genentech. Prior to her current work in USMA, Rita led the Study Review Team for a planned tominersen study in late onset Huntington's Disease, being responsible for developing the protocol and study set up. Before USMA, Rita was in the Product Development OMNI LEAD safety group as Safety Medical Director leading the safety strategy for the initiation and execution of a number of therapeutic areas including the anti-tau molecule semorinemab. Rita obtained her undergraduate degree in theology and biology from University of Rochester, and her Medical Degree at Southern Illinois University School of Medicine. She completed her internship at Illinois Advocate Masonic hospital in Chicago, a year of Physical Medicine and Rehabilitation at Stanford and neurology residency at the University of California, San Diego. She has an additional neurology subspecialty training in movement disorders from Georgetown University. She subsequently practiced clinical neurology, as the Director of the Movement Disorder program at Marshall University in Huntington, West Virginia. There she developed a comprehensive movement program including Deep Brain Stimulation and other treatment modalities including comprehensive inpatient and outpatient care for Parkinson's disease and Huntington's disease patients. To find out if you can join the clinical trial, or for more information, please speak to your  doctor today or contact the Genentech Trial Information Support Line  (TISL) at 888-662-6728 (Monday - Friday, 5am - 5pm PT). Or https://clinicaltrials.gov/ trial #NCT05686551